The Effect of Neoadjuvant Chemotherapy on HIF-1α Expression in Cervical Uterine Cancer

Authors

  • Ika Wiraswesty Department of Obstetrics dan Gynecology, Faculty of Medicine, Universitas Sebelas Maret/ Dr. Moewardi Hospital, Surakarta
  • Supriyadi Hari Respati Department of Obstetrics dan Gynecology, Faculty of Medicine, Universitas Sebelas Maret/ Dr. Moewardi Hospital, Surakarta
  • Sri Sulistyowati Department of Obstetrics dan Gynecology, Faculty of Medicine, Universitas Sebelas Maret/ Dr. Moewardi Hospital, Surakarta
  • Heru Priyanto Department of Obstetrics dan Gynecology, Faculty of Medicine, Universitas Sebelas Maret/ Dr. Moewardi Hospital, Surakarta

Abstract

Background: Uterine cervical cancer is one of the main causes of female death related to cancer. Neoadjuvant chemotherapy aims to reduce tumor mass to allow radical surgery. HIF-1α is thought to have a key role in the development of cancer and the main target for chemoprevention.

Objective: This study aims to prove the effect of neoadjuvant chemotherapy on HIF-1α expression in uterine cervical cancer as an assessment parameter for chemotherapy response. Subjects and methods: The study was carried out in the Department of Obstetrics and Gynecology and the Pathology Department of Anatomy Dr. Moewardi - Faculty of Medicine, Sebelas Maret University, Surakarta. Thirty (30) cervical cancer samples that met the inclusion and exclusion criteria were examined for HIF-1α expression before and after giving 3 times neoadjuvant chemotherapy. Examination using immunohistochemical methods. Data analysis using t-test.

Results: Mean HIF-1α expression before administration of neoadjuvant chemotherapy 5.10± 1.174 cell/field, after administration of neoadjuvant chemotherapy 4.00±1.174 cell/field with p=0.001.

Conclusion: Neoadjuvant chemotherapy has an effect on reducing HIF-1α expression in uterine cervical cancer.

Keywords: neoadjuvant chemotherapy, HIF-1α, uterine cervical cancer

Correspondence: Sri Sulistyowati. Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Sebelas Maret. Mobile: 08122968215. email: elis_spog@yahoo.co.id 

Indonesian Journal of Medicine (2018), 3(2): 119-124
https://doi.org/10.26911/theijmed.2018.03.02.08

References

Andrijono (2016). Kanker Serviks. Bab V. Edisi 5. Badan Penerbit Fakultas Kedokteran Universitas Indonesia, jakarta. 95-119.

Berman N (2015), Association of Reproductive Health Profesional. (2015). HPV and Cervical Cancer. ARHP clinical proceeding.

Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G (2000). Overexpression of Hypoxia-inducible Factor 1 α Is a Marker for an Unfavorable Prognosis in EarlyStage Invasive Cervical Cancer Advances in Brief Prognosis in EarlyStage Invasive Cervical Cancer Res. 60 (17):46936.

Chen P, Jiao L, Wang D (2017). Squamous cell carcinoma antigen expression in tumor cells is associated with the chemosensitivity and survival of patients with cervical cancer receiving docetaxelcarboplatin based neoadjuvant chemotherapy,Oncol Lett. 13(3): 1235–1241. doi: 10.3892/ol.2017.5560.

dos Santos M, Mercante AM, Louro ID, et al. (2012). HIF1alpha expression predicts survival of patients with squamous cell carcinoma of the oral cavity. PLoS One. 2012;7(9):e45228. doi: 10.1371/journal.pone.0045228

Hyngstrom JR, Posner MC (2010). Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. J Surg Oncol. 101(4):299-304. doi: 10.1002/jso.21479.

Koh WJ. (2016). National Comprehensive Cancer Network (NCCN) Cervical Cancer. Version I.2016. NCCN Clinical Practice Guidelines in Oncology.

Onnis B, Rapisarda A and Melillo G. (2009). Development of HIF-1 inhi-bitors for cancer therapy. J Cell Mol Med. 13(9A): 2780–2786. doi: 10.1111/j.15824934.2009.00876.x.

Poon E, Harris AL and Ashcroft M. (2009). Targeting the hypoxiainducible factor (HIF) pathway in cancer.Expert Rev Mol Med. 11:e26. doi: 10.1017/S1462399409001173.

Ruihua T, Yongqiang L and Zongzhu Z. (2017). The study of correlation between neoadjuvant chemotherapy and the expression of VEGF, HIF1α and MVD in breast cancer.Biomedical Research. Special Issue: S537S541.

Stefani L, Galanti G, Klika R (2017). Clinical Implementation of Exercise Guidelines for Cancer Patiens: Adaptation of ACSM's Guidelines to the Italian Model. J. Funct. Morphol. Kinesiol; 2(4):2017

Wardani EK (2014).Respon Fisik dan Psikologi Wanita dengan Kanker Serviks yang Telah Mendapat Kemoterapi di RSUD Dr. Moewardi Surakarta. [Skripsi] Surakarta: FK UNS.

World Health Organisation. (2014). Comprehensive Cervical Cancer Control. A guide to essential practice – 2nd edition. http://www.who.int/repro-ductivehealth/publications/cancers/-cervical-cancer-guide/en/

Downloads

Published

2018-07-01

Issue

Section

Articles